Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company based in New York. The company focuses on discovering and developing targeted small molecule therapeutics for central nervous system (CNS) diseases that have significant unmet needs. Anavex utilizes a precision medicine platform, analyzing genomic data from clinical trials to identify biomarkers that guide the design and analysis of trials for various neurodegenerative and neurodevelopmental diseases. The company is advancing its pipeline of investigational compounds, including ANAVEX®2-73 (blarcamesine), which targets Alzheimer’s disease and enhances the body's natural defenses through the activation of the Sigma-1 receptor. Anavex is also developing therapies for other CNS conditions, such as Parkinson’s disease, schizophrenia, and rare diseases like Rett syndrome. The company emphasizes precision therapeutics, scientific innovation, and equitable access in its mission to address challenging CNS disorders across all ages.